Gofen & Glossberg LLC IL raised its position in shares of Pfizer Inc. (NYSE:PFE) by 0.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 480,157 shares of the biopharmaceutical company’s stock after purchasing an additional 3,213 shares during the quarter. Gofen & Glossberg LLC IL’s holdings in Pfizer were worth $17,391,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $103,000. Herndon Capital Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $120,000. Americafirst Capital Management LLC bought a new stake in shares of Pfizer in the 3rd quarter valued at approximately $127,000. Private Vista LLC lifted its stake in shares of Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 190,933 shares during the last quarter. Finally, Lipe & Dalton lifted its stake in shares of Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 71.41% of the company’s stock.
In other news, insider Kirsten Lund-Jurgensen sold 9,510 shares of Pfizer stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares in the company, valued at approximately $1,374,505.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 185,464 shares of company stock valued at $6,767,939. 0.06% of the stock is currently owned by corporate insiders.
Shares of Pfizer Inc. (PFE) opened at $36.61 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $217,930.00, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 2.07 and a beta of 0.91. Pfizer Inc. has a 1 year low of $31.67 and a 1 year high of $39.43.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. Pfizer’s revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company posted $0.47 EPS. equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer declared that its Board of Directors has initiated a share buyback plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a yield of 3.71%. Pfizer’s payout ratio is 77.71%.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3259013/pfizer-inc-pfe-shares-bought-by-gofen-glossberg-llc-il.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.